The historical data trend for Arcus Biosciences's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RCUS vs NAMS, CRNX, CPRX: Buyback Yield % Comparison
For the Biotechnology subindustry, Arcus Biosciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcus Biosciences Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences (RCUS) has a Buyback Yield % of -7.40 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Arcus Biosciences and its competitors. According to the industry distribution chart, Arcus Biosciences ranks #347 out of 745 companies in the Biotechnology industry, placing it in the top 46.6%.
Is Arcus Biosciences' Buyback Yield % too high?
Arcus Biosciences' current Buyback Yield % is -7.40. Based on the distribution chart, Arcus Biosciences ranks #347 out of 745 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arcus Biosciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' Buyback Yield % compare to NAMS and CRNX?
According to the Biotechnology industry distribution chart, Arcus Biosciences ranks #347 out of 745 companies for Buyback Yield %. This puts Arcus Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Arcus Biosciences and its competitors. Arcus Biosciences's current Buyback Yield % is -7.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.54, compared to a current price of $29.69 — trading 119.3% above its estimated fair value. The current Buyback Yield % is -7.40. Arcus Biosciences' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current Buyback Yield % is -7.40 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcus Biosciences (RCUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued.
The current stock price of $29.69 is trading 119.3% above its estimated GF Value™ of $13.54.
GuruFocus considers Arcus Biosciences to be Significantly Overvalued.
Key valuation signals for RCUS:
Buyback Yield %: -7.40
GF Value™: $13.54 vs. price of $29.69 (119.3% above fair value)
No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score
Get the complete analysis for RCUS
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RCUS has been successfully added to your 
